Original Research ArticleInternational Journal of Research in Medical Sciences

Publication:
Ovarian reserve and markers after chemotherapy in young women with early-stage breast cancer

Int J Res Med Sci. 2026;14(3):791-797.DOI10.18203/2320-6012.ijrms20260590

Thumbnail Image
View on the journal's website(opens in a new tab)

Abstract

Background The aim of the study was to compare ovarian reserve and its markers between young women who received chemotherapy for early-stage breast cancer and healthy controls.

Methods This cross-sectional study was conducted at Gülhane Military Medical Academy (GATA, currently Ankara Gülhane Training and Research Hospital), Ankara, Türkiye, between December 2010 and October 2011.  Ovarian reserve was evaluated in 34 women with early-stage breast cancer who resumed regular menstruation after chemotherapy and compared with 34 age- and gravida-matched healthy controls. Main outcome measures included antral follicle count (AFC), total ovarian volume, anti-Müllerian hormone (AMH), FSH, and estradiol (E2) levels on days 2 or 3 of the menstrual cycle.

Results The median AFC was 5 in the cancer group and 7 in the controls. AMH, AFC, ovarian volume, and FSH levels significantly differed between groups, favoring the controls. A significant difference in E2 levels was also noted. AFC and AMH were strongly correlated (r=0.84 and r=0.74, respectively). Multivariate logistic regression identified AFC as the strongest predictor of AMH.

Conclusions Chemotherapy for early-stage breast cancer is associated with reduced ovarian reserve in young women despite the continuation of menstruation.

Keywords

Affiliations

  1. Department of Obstetrics and Gynecology, Gülhane Training and Research Hospital, Health Sciences University, Ankara, Turkey
  2. Department of Obstetrics and Gynecology, Gülhane Askeri Tıp Akademisi (GATA), Ankara, Turkey

Full item record